BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

5162

543321

TATVA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

TATVA CHIN PHARM CHEM LTD performance

Today’s low

Today’s high

₹ 701.30 ₹ 730.00
₹ 704.50

52 week low

52 week high

₹ 621.00 ₹ 1283.70
₹ 704.50

Open Price

₹ 727.40

Prev. Close

₹ 723.55

Volume (Shares)

14765.00

Total traded value

₹ 104.01

Upper Circuit

₹ 868.25

Lower Circuit

₹ 578.85

info

TATVA CHIN PHARM CHEM LTD Share Price Update

As of the latest trading session, TATVA CHIN PHARM CHEM LTD share price is currently at ₹ 704.5, which is down by ₹ -19.04 from its previous closing. Today, the stock has fluctuated between ₹ 701.30 and ₹ 730.00. Over the past year, TATVA CHIN PHARM CHEM LTD has achieved a return of -42.63 %. In the last month alone, the return has been -0.38 %. Read More...

TATVA CHIN PHARM CHEM LTD fundamentals


  • Market cap (Cr)

    1,647.97

  • P/E Ratio (TTM)

    220.63

  • Beta

    0.45

  • Book Value / share

    308.43

  • Return on equity

    4.77%

  • EPS (TTM)

    3.20

  • Dividend yield

    0.28%

  • Net profit/quarter (Cr)

    -1.17

info icon alternate text
  • Market cap (Cr)

    1,656.15

  • P/E Ratio (TTM)

    220.63

  • Beta

    0.37

  • Book Value / share

    308.43

  • Return on equity

    4.77%

  • EPS (TTM)

    3.20

  • Dividend yield

    0.28%

  • Net profit/quarter (Cr)

    -1.17

info icon alternate text

TATVA CHIN PHARM CHEM LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 84.00
Operating Expense 85.70
Net Profit -1.17
Net Profit Margin (%) -1.39
Earnings Per Share (EPS) -0.50
EBITDA 5.68
Effective Tax Rate (%) 29.69
Particulars SEP 2024 (Values in Cr)
Revenue 80.96
Operating Expense 83.34
Net Profit -1.11
Net Profit Margin (%) -1.37
Earnings Per Share (EPS) -0.47
EBITDA 5.39
Effective Tax Rate (%) 29.74
Particulars JUN 2024 (Values in Cr)
Revenue 93.81
Operating Expense 93.09
Net Profit 1.51
Net Profit Margin (%) 1.60
Earnings Per Share (EPS) 0.64
EBITDA 9.11
Effective Tax Rate (%) 29.43
Particulars MAR 2024 (Values in Cr)
Revenue 93.93
Operating Expense 86.17
Net Profit 8.25
Net Profit Margin (%) 8.78
Earnings Per Share (EPS) 3.52
EBITDA 18.73
Effective Tax Rate (%) 32.81
Particulars DEC 2023 (Values in Cr)
Revenue 86.07
Operating Expense 80.72
Net Profit 4.65
Net Profit Margin (%) 5.40
Earnings Per Share (EPS) 1.99
EBITDA 13.52
Effective Tax Rate (%) 29.11
Particulars MAR 2024 (Values in Cr)
Revenue 378.68
Operating Expense 343.92
Net Profit 29.35
Net Profit Margin (%) 7.75
Earnings Per Share (EPS) 12.82
EBITDA 74.38
Effective Tax Rate (%) 30.56
Particulars MAR 2023 (Values in Cr)
Revenue 403.04
Operating Expense 366.30
Net Profit 40.47
Net Profit Margin (%) 10.04
Earnings Per Share (EPS) 18.26
EBITDA 56.76
Effective Tax Rate (%) -4.19
Particulars MAR 2022 (Values in Cr)
Revenue 427.81
Operating Expense 335.17
Net Profit 95.99
Net Profit Margin (%) 22.43
Earnings Per Share (EPS) 44.65
EBITDA 116.40
Effective Tax Rate (%) 7.04
Particulars MAR 2021 (Values in Cr)
Revenue 291.19
Operating Expense 236.94
Net Profit 51.36
Net Profit Margin (%) 17.63
Earnings Per Share (EPS) 25.57
EBITDA 70.29
Effective Tax Rate (%) 13.46
Particulars MAR 2020 (Values in Cr)
Revenue 253.84
Operating Expense 210.18
Net Profit 34.96
Net Profit Margin (%) 13.77
Earnings Per Share (EPS) 17.41
EBITDA 52.94
Effective Tax Rate (%) 20.91
Particulars MAR 2024 (Values in Cr)
Book Value / Share 315.10
ROE % 4.85
ROCE % 6.99
Total Debt to Total Equity 0.15
EBITDA Margin 19.29
Particulars MAR 2023 (Values in Cr)
Book Value / Share 232.25
ROE % 9.21
ROCE % 8.34
Total Debt to Total Equity 0.29
EBITDA Margin 14.86
Particulars MAR 2022 (Values in Cr)
Book Value / Share 213.44
ROE % 30.00
ROCE % 25.64
Total Debt to Total Equity 0.33
EBITDA Margin 27.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share 82.62
ROE % 36.85
ROCE % 27.90
Total Debt to Total Equity 0.64
EBITDA Margin 23.93
Particulars MAR 2020 (Values in Cr)
Book Value / Share 146.48
ROE % 38.29
ROCE % 28.34
Total Debt to Total Equity 0.85
EBITDA Margin 21.52
Particulars MAR 2024 (Values in Cr)
Book Value / Share 310.31
ROE % 4.77
ROCE % 6.90
Total Debt to Total Equity 0.15
EBITDA Margin 19.68
Particulars MAR 2023 (Values in Cr)
Book Value / Share 227.74
ROE % 8.31
ROCE % 7.48
Total Debt to Total Equity 0.30
EBITDA Margin 14.12
Particulars MAR 2022 (Values in Cr)
Book Value / Share 211.54
ROE % 30.43
ROCE % 25.71
Total Debt to Total Equity 0.33
EBITDA Margin 27.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 80.61
ROE % 37.16
ROCE % 27.74
Total Debt to Total Equity 0.65
EBITDA Margin 24.21
Particulars MAR 2020 (Values in Cr)
Book Value / Share 142.44
ROE % 36.02
ROCE % 26.72
Total Debt to Total Equity 0.86
EBITDA Margin 20.98
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 38.29
Total Assets 818.71
Total Liabilities 818.71
Total Equity 737.08
Share Outstanding 23392055
Price to Book Ratio 3.48
Return on Assets (%) 3.70
Return on Capital (%) 4.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 44.76
Total Assets 758.85
Total Liabilities 758.85
Total Equity 514.79
Share Outstanding 22165062
Price to Book Ratio 7.32
Return on Assets (%) 5.99
Return on Capital (%) 6.64
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 176.98
Total Assets 658.30
Total Liabilities 658.30
Total Equity 473.08
Share Outstanding 22165062
Price to Book Ratio 10.91
Return on Assets (%) 14.56
Return on Capital (%) 16.17
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.34
Total Assets 314.80
Total Liabilities 314.80
Total Equity 165.96
Share Outstanding 20087500
Price to Book Ratio 0.00
Return on Assets (%) 16.60
Return on Capital (%) 20.4
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 10.82
Total Assets 248.93
Total Liabilities 248.93
Total Equity 117.69
Share Outstanding 8035000
Price to Book Ratio 0.00
Return on Assets (%) 15.18
Return on Capital (%) 19.19
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 36.97
Total Assets 815.06
Total Liabilities 815.06
Total Equity 725.88
Share Outstanding 23392055
Price to Book Ratio 3.48
Return on Assets (%) 3.60
Return on Capital (%) 3.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 38.58
Total Assets 754.85
Total Liabilities 754.85
Total Equity 504.78
Share Outstanding 22165062
Price to Book Ratio 7.32
Return on Assets (%) 5.36
Return on Capital (%) 5.99
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 174.74
Total Assets 676.20
Total Liabilities 676.20
Total Equity 468.87
Share Outstanding 22165062
Price to Book Ratio 10.91
Return on Assets (%) 14.19
Return on Capital (%) 16.3
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.58
Total Assets 309.68
Total Liabilities 309.68
Total Equity 161.93
Share Outstanding 20087500
Price to Book Ratio 0.00
Return on Assets (%) 16.58
Return on Capital (%) 20.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 9.81
Total Assets 245.30
Total Liabilities 245.30
Total Equity 114.44
Share Outstanding 8035000
Price to Book Ratio 0.00
Return on Assets (%) 14.25
Return on Capital (%) 18.06
Particulars MAR 2024 (Values in Cr)
Net Income 43.56
Cash from Operations 107.90
Cash from Investing -120.54
Cash from Financing 30.51
Net change in Cash 8.02
Free Cash Flow 236.41
Particulars MAR 2023 (Values in Cr)
Net Income 44.77
Cash from Operations 37.07
Cash from Investing -101.14
Cash from Financing 37.79
Net change in Cash -35.56
Free Cash Flow 240.18
Particulars MAR 2022 (Values in Cr)
Net Income 104.12
Cash from Operations 38.78
Cash from Investing -196.80
Cash from Financing 234.96
Net change in Cash 58.53
Free Cash Flow 127.94
Particulars MAR 2021 (Values in Cr)
Net Income 60.69
Cash from Operations 29.50
Cash from Investing -20.65
Cash from Financing -4.71
Net change in Cash -5.67
Free Cash Flow 50.47
Particulars MAR 2020 (Values in Cr)
Net Income 47.59
Cash from Operations 33.51
Cash from Investing -40.18
Cash from Financing 9.95
Net change in Cash -4.91
Free Cash Flow 81.68
Particulars MAR 2024 (Values in Cr)
Net Income 42.26
Cash from Operations 111.02
Cash from Investing -120.54
Cash from Financing 30.54
Net change in Cash 12.78
Free Cash Flow 239.53
Particulars MAR 2023 (Values in Cr)
Net Income 38.83
Cash from Operations 31.47
Cash from Investing -101.12
Cash from Financing 37.81
Net change in Cash -39.57
Free Cash Flow 234.55
Particulars MAR 2022 (Values in Cr)
Net Income 103.26
Cash from Operations 37.72
Cash from Investing -196.68
Cash from Financing 235.01
Net change in Cash 58.04
Free Cash Flow 126.88
Particulars MAR 2021 (Values in Cr)
Net Income 59.34
Cash from Operations 28.72
Cash from Investing -20.61
Cash from Financing -4.71
Net change in Cash -6.42
Free Cash Flow 49.69
Particulars MAR 2020 (Values in Cr)
Net Income 44.21
Cash from Operations 32.02
Cash from Investing -40.18
Cash from Financing 9.70
Net change in Cash -5.84
Free Cash Flow 80.19
Company Name Price P/E P/B Market Cap 52 Week Low/High
ATUL LTD 6736.35 40.98 3.54 19833.00 4882.00 / 8165.25
BASF INDIA LTD 4386.10 31.46 5.41 18985.51 3715.95 / 8748.10
ORIENTAL AROMATICS LTD 336.30 26.31 1.72 1131.77 252.40 / 656.00
DEEPAK FERTILIZERS & PETR 1279.25 18.54 2.84 16148.97 500.85 / 1443.35
Company Name Price P/E P/B Market Cap 52 Week Low/High
ADVANCE PETROCHEMICALS LTD. 171.00 58.56 4.19 15.39 168.50 / 330.00
ATUL LTD 6736.35 43.47 3.58 19833.00 4882.00 / 8165.25
BASF INDIA LTD 4386.10 31.46 5.41 18985.51 3715.95 / 8748.10
ORIENTAL AROMATICS LTD 336.30 23.16 1.71 1131.77 252.40 / 656.00

TATVA CHIN PHARM CHEM LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
704.50 -2.63 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 720.20
  • 26 Days 712.60
  • 10 Days 720.40
  • 50 Days 722.00
  • 12 Days 719.10
  • 100 Days 767.10
  • 20 Days 714.10
  • 200 Days 874.20
726.82 PIVOT

First Support

718.13

First Resistance

732.23

Second Support

712.72

Second Resistance

740.92

Third Support

704.03

Third Resistance

746.33

RSI

48.07

ADX

20.15

MACD

6.45

Williams % R

-55.91

Commodity Channel Index (CCI)

6.93

Date

2025-04-30

Week

10449.00

Same Day

5592.00

Month

12235.00

1 Year

0.46

3 Year

0.60

Over 1 Month

-0.38%

down

Over 1 Year

-42.63%

down

Over 3 Months

-9.20%

down

Over 3 Years

-32.71%

down

Over 6 Months

-12.76%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

TATVA CHIN PHARM CHEM LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
19.21%
Promoter Holdings
72.02%
FII
3.29%
DII
5.46%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shekhar Rasiklal Somani 5396861.0 (23.07%) Shareholding of Promoter and Promoter Group
Chintan Nitinkumar Shah 4897219.0 (20.94%) Shareholding of Promoter and Promoter Group
Ajay Mansukhlal Patel 4000000.0 (17.1%) Shareholding of Promoter and Promoter Group
Priti Ajay Patel 900000.0 (3.85%) Shareholding of Promoter and Promoter Group
Nippon Life India Trustee Ltd-a/c Nippon India Elss Tax Saver Fund 773774.0 (3.31%) Public Shareholding
Ajay Mansukhlal Patel (huf) 715345.0 (3.06%) Shareholding of Promoter and Promoter Group
Goldman Sachs Funds - Goldman Sachs India Equity Portfolio 606662.0 (2.59%) Public Shareholding
Icici Prudential Smallcap Fund 475967.0 (2.03%) Public Shareholding
Chintan N Shah (huf) 447500.0 (1.91%) Shareholding of Promoter and Promoter Group
Shital Chintan Shah 231000.0 (0.99%) Shareholding of Promoter and Promoter Group
Kajalben Shekharkumar Somani 218080.0 (0.93%) Shareholding of Promoter and Promoter Group
Darshana Nitinkumar Shah 39628.0 (0.17%) Shareholding of Promoter and Promoter Group
Somani Samir Rasiklal 482.0 (0.0%) Shareholding of Promoter and Promoter Group
Shitalbhai Rasiklal Somani 843.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

TATVA CHIN PHARM CHEM LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Sep 2023 2.0 Final 08 Sep 2023 Equity shares
08 Sep 2022 2.0 Final 09 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Sep 2023 2.0 Final 08 Sep 2023 Equity shares
08 Sep 2022 2.0 Final 09 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

TATVA CHIN PHARM CHEM LTD Share Price

Tatva Chintan Pharma Chem Limited was formerly incorporated as 'Tatva Chintan Pharma Chem Private Limited' on 12 June 1996. The status of the Company converted from Private Limited into a Public Limited Company effective from 27 January 2021 and the name of Company also changed from 'Tatva Chintan Pharma Chem Private Limited' to 'Tatva Chintan Pharma Chem Limited'. The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani.

The Company is a globally recognized specialty chemical player with several market leading products in its portfolio. The Company is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), , Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC). These products cater to diverse industries such as pharmaceuticals, agrochemicals, automotive, electronics, resins and polymers, flavours and fragrances, personal care and disinfectants, oil field and energy storage.

The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located very close to the Hazira Port. These units provide the Company cost and logistics advantage and enabling seamless export and import operations. The Company's manufacturing facilities obtained ISO 9001:2015 and 14001:2015 certification for robust quality management systems. Employing modern equipment like reactors, assembly lines, ANFDs, centrifuges and RCVDs, enabled the Company to undertake multiple chemistry process. The Company successfully established an integrated model comprising world class manufacturing infrastructure, complex & chemical processes, warehousing facilities and technically sound R&D capabilities, which enables to achieve high operational efficiency and quality, to innovate & customize and to ensure sustainable operations with wide offerings. The Company has sophisticated quality control lab equipped with modern analytical equipment, enabling it to detect impurities upto PPM levels and achieve ultra-pure'grade certification. The Company Promoters identified an opportunity in manufacturing Phase Transfer Catalyst (PTC), which is a niche segment within the specialty chemicals space. With PTC as the base, the Company have marked presence in the entire value chain including PTC, Structure Directing Agents (SDA), Electrolyte Salts (ES) and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).

The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved R&D centre at its Vadodara facility where qualified and experienced in-house R&D team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with state-of-the-art instrumentation.

In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant.
In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity.
In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA).
In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs & Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL.
In 2016, the Company was accorded the status of a two-star export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI).
In 2017, manufacturing plant was established in Dahej, Gujarat.
In 2018, the R&D facility was set up in Vadodara.
Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019.
In FY 2019-20, the Company's Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower by-products and waste generation in chemical processes.
Additionally, the Company participated in the Together for Sustainability' initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business.
In 2020, the Company achieved another Rs 2 billion revenue.
In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively.

The Company launched its Initial Public Offer cum Offer for Sale of 46,16,804 Equity Shares by raising funds from public aggregating to Rs 500 Crore, comprising a Fresh Issue of 20,77,562 Equity Shares aggregating to Rs 225 Crore and an Offer for Sale of 25,39,242 Equity Shares aggregating to Rs 275 Crore in July, 2021.

The Company commenced commercial production from the newly expanded facility at Dahej SEZ. With this, the installed reactor capacity increased to 500 KL from 294 KL and assembly lines increased from 27 to 39 in 2023-24.

Parent organization Indian Private
NSE symbol TATVA
Founded 1996
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Tatva Chintan Pharma Chem Ltd?

Answer Field

The share price of Tatva Chintan Pharma Chem Ltd for NSE is ₹ 704.5 and for BSE is ₹ 708.

What is the Market Cap of Tatva Chintan Pharma Chem Ltd?

Answer Field

The market cap of Tatva Chintan Pharma Chem Ltd for NSE is ₹ 16,47.97 Cr. and for BSE is ₹ 16,56.15 Cr. as of now.

What is the 52 Week High and Low of Tatva Chintan Pharma Chem Ltd?

Answer Field

The 52 Week High and Low of Tatva Chintan Pharma Chem Ltd for NSE is ₹ 1283.70 and ₹ 621.00 and for BSE is ₹ 1280.00 and ₹ 610.00.

How to Buy Tatva Chintan Pharma Chem Ltd share?

Answer Field

You can trade in Tatva Chintan Pharma Chem Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Tatva Chintan Pharma Chem Ltd?

Answer Field

The 1 year returns on the stock has been -42.63%.

What is the Current Share Price of Tatva Chintan Pharma Chem Ltd?

Answer Field

Tatva Chintan Pharma Chem Ltd share price is for NSE ₹ 704.5 & for BSE ₹ 708 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Tatva Chintan Pharma Chem Ltd Share?

Answer Field

The market cap of Tatva Chintan Pharma Chem Ltd for NSE ₹ 16,47.97 & for BSE ₹ 16,56.15 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Tatva Chintan Pharma Chem Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Tatva Chintan Pharma Chem Ltd share is 220.63.

What is the PB ratio of Tatva Chintan Pharma Chem Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Tatva Chintan Pharma Chem Ltd share is 308.43.

How to Buy Tatva Chintan Pharma Chem Ltd Share?

Answer Field

You can trade in Tatva Chintan Pharma Chem Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Tatva Chintan Pharma Chem Ltd Share on Bajaj Broking App?

Answer Field

To buy Tatva Chintan Pharma Chem Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Tatva Chintan Pharma Chem Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|